University of Wisconsin–Madison

ACRIN6686/RTOG0825 Phase III Double Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme Tumors

March 2010 to December 2011

This study is for persons with newly diagnosed glioblastoma multiforme (GBM) tumors who will be treated on a phase III Radiation Therapy Oncology Group (RTOG) treatment protocol. If persons participate in the treatment protocol, they will have the opportunity to participate in the advanced imaging portion of the trial that looks at the ability of MRI to assess tumor changes utilizing new imaging sequences.

This project led by: Howard A Rowley MD